3.4 News

October 4, 2018

Tempus and Mary Crowley Cancer Research Launch a New Lung Cancer Initiative

October 4 – Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data and Mary Crowley Cancer Research have announced a new collaboration with the objective of expanding research options for lung cancer patients. As part of this collaboration, Tempus...

September 19, 2018

Tempus Launches New Mobile App to Make Clinical and Genomic Data More Accessible to Physicians at the Point of Care

CHICAGO, Sept. 19, 2018 (GLOBE NEWSWIRE) — Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, today announced the launch of its new mobile app, Tempus Labs, which will extend the reach of the Tempus platform, enabling physicians to securely ac...

September 14, 2018

Tempus Adds Tempus xF, a Liquid Biopsy Assay, to Sequencing Capabilities

September 14 – Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, has added a non-invasive genomic sequencing panel, Tempus xF, a liquid biopsy cell-free DNA assay that analyzes 77 genes, to its sequencing capabilities.. Tempus xF will be run in the company’s state-of...

August 30, 2018

Groupon Cofounder’s Health Startup Hits $2 Billion Valuation With Latest Funding Round

Tempus, a startup using data analytics to improve cancer treatment, raised $110 million in its Series E financing, the company announced Wednesday. Its third fundraise in 11 months, this round brings the company’s valuation to about $2 billion. To date Tempus has raised $320 million since it was founded by GrouponGRPN -0.33% co...

August 29, 2018

Tempus Announces $110 Million in Series E Financing

CHICAGO, Aug. 29, 2018 (GLOBE NEWSWIRE) — Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today it has secured an additional $110 million in financing at a valuation of $2 billion dollars. The round includes Baillie Gifford, funds and account...

August 23, 2018

Tempus to Collaborate with CancerLinQ LLC and U.S. Food and Drug Administration on Checkpoint Inhibitors

Alexandria, Va. — CancerLinQ LLC, a wholly-owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO), has brought on technology collaborators Concerto HealthAI and Tempus to accelerate its joint research effort with the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) aimed at understanding the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors. Concerto HealthAI and Tempus have begun to assist in the analysis of a de-identified dat...

August 2, 2018

Tempus to Participate in the NCI-MATCH Clinical Trial

Having met rigorous qualifications, Tempus joins a select group of commercial and academic laboratories designated to cast a wider net for patients to enter the trial CHICAGO, Aug. 02, 2018 (GLOBE NEWSWIRE) — Tempus announced today that it is participating as a CLIA-certified/accredited laboratory for the NCI-Molecular Analys...

May 8, 2018

Tempus Announces New Initiative to Support Physicians Efforts to Deliver Personalized Medicine

CHICAGO, May 08, 2018 (GLOBE NEWSWIRE) — Tempus today announced a new initiative that will allow physicians to sequence a second patient sample without additional charge, removing a barrier that oftentimes stands in the way of a patient being sequenced.The Tempus xT panel analyzes 595 genes relevant to th...

March 20, 2018

Tempus Announces Additional $80 Million in Financing

Chicago, March 20 – Tempus announced today it has raised an additional $80M in financing. The round included existing investors, New Enterprise Associates and Revolution Growth, along with new investors Kinship Trust Company and funds advised by T. Rowe Price Associates, Inc. The additional funds will be used to further...

February 22, 2018

Tempus Launches Tempus xE, Whole Exome Sequencing to Empower Data-Driven Cancer Care and Research

CHICAGO, Feb. 22, 2018 (GLOBE NEWSWIRE) — Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, has launched a new genomic sequencing panel, Tempus xE, which analyzes the whole exome in a CLIA/CAP validated assay...

Show More